~~<i id='D91F778F2A'><strike id='D91F778F2A'><tt id='D91F778F2A'><pre id='D91F778F2A'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：focus 2025-10-01 19:07:22 Page View：87

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Lack of darker skin in textbooks, journals harms patients of color
Next article： Activists slam private health insurers over coverage restrictions

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Diversity in clinical trials starts with building trust, experts say

SilasBuchanan,CEOofOurHealthyCommunity,speaksonapanelaboutdemocratizingclinicaltrialsattheMilkenInst

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Key Senate committee drafts bipartisan bill to stem drug shortages

AdobeWASHINGTON—TheSenateFinanceCommitteehasdraftedabipartisanbilltomitigatedrugshortagesbyrewarding